ArticleAmerican journal of translational research2021
The correlation of the miR-29a/MMP9 axis with
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Identification of anti-gastric cancer effects and molecular mechanisms of resveratrol: From network pharmacology and bioinformatics to experimental validation.World journal of gastrointestinal oncology · 2024Article
- The Most Recent Insights into the Roots of Gastric Cancer.Life (Basel, Switzerland) · 2024Review
- Pulmonary microbiota signatures adjacent to adenocarcinoma, squamous cell carcinoma and benign lesion.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to investigate the association between the miR-29a/MMP9 axis expression levels and
methodsA total of 100 gastric cancer patients referred to our hospital from June 2017 to June 2019 were recruited as the study cohort. Among them, 50 HP-positive patients were included in the experimental group and 50 HP-negative patients were included in the control group. The changes in the patients' conditions were compared, the miR-29a/MMP9 axis expression levels were recorded, and the correlation between the miR-29a/MMP9 axis and the HP infections was analyzed. All the discharged patients were followed up for one year to analyze the correlation between the HP infections and the serum miR-29a and MMP9 expression levels with the disease progression.
resultsThe experimental group had higher miR-29a expression levels and higher MMP9 chromogenic scores than the control group (P<0.05). A negative correlation was found between the miR-29 expression level and the MMP9 expression level (r=-5.369, P<0.05). One year after discharge, there were 27 patients with severe disease in the experimental group and 6 in the control group, with a significant difference between the two groups. Moreover, the expression levels of the miR-29a/MMP9 axis were significantly higher in the discharged patients than in the patients with severe disease (P<0.05). A receiver operating characteristic (ROC) curve was used to analyze the predictive value of miR-29/MMP9 in the diagnosis of gastric cancer, and the area under the curve was found to be 0.97.
conclusionThe miR-29a/MMP9 axis levels were increased in the HP positive patients but not in the HP negative patients. HP infection is considered to be closely related to gastric cancer cell spread, disease relapse, and high miR-29a/MMP9 axis expression levels.
Indexed as
Identifiers
34650687PMC8506987W3207005771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.